The new kits enable PCR amplification of genes known to be frequently mutated in tumor tissue of highly prevalent cancers of the gastro-intestinal track, colon, lung and skin. Based on this amplified material, the DNA sequence of the genes can then be determined allowing physicians to identify all mutations and subsequently select the most effective treatment for the patient.
The new kits are based on Multiplicom's proprietary MASTR(TM) technology: Epidermal Growth Factor (EGFR 18-21); Gastro-Intestinal Stromal Tumors (GIST) (cKIT, PDGFRA) and Somatic panel 1 (KRAS, NRAS, BRAF) and complement Multiplicom's MASTR product line which can be used in combination with all commercial bench top MPS instruments.
Multiplicom is operating in an area of rapid growth. The European MPS diagnostic market is expected to grow from
About the somatic mutation kits
EGFR is frequently hyperactive in a number of cancers [http://en.wikipedia.org/wiki/Cancer ], including lung cancer [http://en.wikipedia.org/wiki/Lung_cancer ], anal cancers [http://en.wikipedia.org/wiki/Anal_cancer ] and glioblastoma [http://en.wikipedia.org/wiki/Glioblastoma_multiforme ]. Drugs such as Iressa [http://en.wikipedia.org/wiki/Iressa ] (gefitinib) and Tarceva [http://en.wikipedia.org/wiki/Tarceva ] (erlotinib) directly target EGFR, but are only found to be effective in the absence of certain mutations that can be identified using the EGFR MASTR kit.
In approximately 80% of GISTs, mutations in the cKIT gene contribute to the growth of the tumor cells. Among tumors that lack a cKIT mutation, some have mutations in a closely related gene called PDGFRA (about 5-7% of all GISTs). Knowledge of the exact type and location of a mutation in the KIT or PDGFRA gene, using the GIST MASTR kit, can be used to predict the likelihood that the tumor will respond to treatment with Gleevec (imatinib).
The Somatic 1 MASTR detects mutations in KRAS, NRAS and BRAF, genes that are part of the RAS-RAF-MAPK signal transduction pathway downstream from EGFR. Wild-type KRAS, wild-type BRAF and NRAS are required for response to anti-EGFR therapy making mutation analysis of all three genes useful.
For further information please visit http://www.multiplicom.com.
For more information please contact:
Most Popular Stories
- Adam Levine Wins Big as 'The Voice' Crowns Champ
- 'Beyonce' Tops the U.S. Album Chart
- Archer Daniels Midland Moving HQ to Chicago
- Target Security Breach May Affect 40 Million Cardholders
- Tyson Foods Charged With Civil Rights Violation
- Bernanke Lets Congress Have It in Final Press Conference
- Wall Street Falls a Day After Surge
- Existing Home Sales Drop for 3rd Month
- Demi Lovato Leaving 'X Factor' to Return to Music
- Jobless Claims Climb by 10,000 in Week